Executive Summary:
Aripiprazole is a second-generation (atypical) antipsychotic with a unique pharmacological profile as a D₂ receptor partial agonist and 5-HT₁A partial agonist. It is FDA-approved for schizophrenia, bipolar I disorder (manic and mixed episodes), adjunctive treatment of major depressive disorder (MDD), irritability associated with autism, and Tourette’s disorder.[1] The FDA label states that published epidemiologic studies have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes.[1] Aripiprazole’s primary advantage in pregnancy is its favorable metabolic profile: the Medicaid cohort study found an adjusted GDM risk ratio of 0.82 (95% CI 0.50–1.33) — the lowest among all SGAs studied, and the only one with a point estimate below 1.0.[2] The Swedish national register study confirmed that “other second-generation antipsychotics” (including aripiprazole) were not associated with metabolic risks.[3] However, aripiprazole carries two unique considerations: (1) a possible neurodevelopmental signal (paHR 1.36 for any NDD; 95% CI 1.14–1.63) that was inconsistent across analyses and could not rule out confounding by indication, and (2) the FDA label explicitly warns that aripiprazole exposure during pregnancy[4] may decrease milk supply in the postpartum period, with a recent clinical study finding 74% complete lactation failure among women who continued aripiprazole through pregnancy and postpartum.[5][6] Additionally, aripiprazole undergoes a 52–77% decline in serum levels by the third trimester, which may necessitate dose adjustment.[7][8]
Reproductive Safety & Teratogenicity
Aripiprazole has a growing but still moderate-sized safety database compared to quetiapine or olanzapine.
- National Pregnancy Registry (Freeman et al., 2021): In the MGH prospective registry, 158 women with first-trimester aripiprazole exposure were compared to 690 controls. The major malformation rate was 4.29% (7/163 infants) in the exposed group vs. 1.99% (14/690) in controls. The unadjusted OR was 2.21 (95% CI 0.88–5.57), but after adjustment for confounders, the adjusted OR was 1.35 (95% CI 0.43–4.20) — not statistically significant. The authors noted these results are “reassuring” but “limited by relatively small numbers.”[9]
- Huybrechts et al. 2016 Medicaid Cohort (1.36 million pregnancies): In this landmark study, atypical antipsychotics as a class showed no increased risk of malformations after confounding adjustment (aRR 1.05; 95% CI 0.96–1.16). Aripiprazole specifically was not associated with an increased risk. The only individual agent with a persistent signal was risperidone.[10]
- Huybrechts et al. 2023 Multinational Cohort (6 countries): In the largest study to date, adjusted relative risks for most antipsychotic-malformation combinations shifted substantially toward the null after propensity score adjustment. For combinations with substantial information, adjusted estimates ranged from 0.7 to 1.2, with the only exception being olanzapine and oral clefts. Aripiprazole did not show a specific malformation signal.[11]
- Network Meta-Analysis (2025): Among 22 studies (3,042,997 pregnancies), aripiprazole had an OR of 1.30 (95% CrI 1.10–1.65) for congenital malformations — higher than quetiapine (1.19) but lower than olanzapine (1.33), risperidone (1.43), or lithium (1.61).[12]
- French Prospective Cohort (Bellet et al., 2015): In 86 aripiprazole-exposed pregnancies vs. 172 matched controls, aripiprazole was not significantly associated with major malformations (OR 2.30; 95% CI 0.32–16.7) or GDM (OR 1.15; 95% CI 0.33–4.04). However, significantly increased rates of prematurity (OR 2.57; 95% CI 1.06–6.27) and fetal growth retardation (OR 2.97; 95% CI 1.23–7.16) were observed, though the authors noted these were difficult to interpret due to short exposure duration and potential confounding.[13]
- FDA Label Summary: “Overall available data from published epidemiologic studies of pregnant women exposed to aripiprazole have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes.” In animal studies, aripiprazole at doses 10× (rats) and 19× (rabbits) the MRHD produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia.[1]
Clinical Pearl — Aripiprazole’s Teratogenicity Profile in Context: Aripiprazole’s malformation data are reassuring but less robust than quetiapine’s. The MGH registry had only 158 exposed women (vs. 152 for quetiapine), and the unadjusted malformation rate of 4.29% was higher than controls, though this was not significant after adjustment.[9] The French cohort raised a signal for prematurity and fetal growth retardation that has not been replicated in larger studies.[13] When counseling patients, aripiprazole can be described as “not established as a teratogen” with a safety profile comparable to other SGAs, but with a smaller evidence base than quetiapine.
Clinical Risks to the Fetus and Neonate
(A) Neonatal Adaptation Syndrome (EPS/Withdrawal)
The FDA class-wide warning applies to aripiprazole: neonates exposed during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms.[1]
- Symptoms: Agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.[1]
- Duration: Symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.[1]
- Aripiprazole-Specific Pattern: As a D₂ partial agonist, aripiprazole’s neonatal adaptation profile is pharmacologically distinct from both full D₂ antagonists (risperidone → hypertonia/tremor) and low-D₂ agents (quetiapine → sedation/hypotonia). The neonatal presentation may include elements of both patterns. The Australian multicenter study (26 women) found higher rates of neonatal admission than expected population rates.[14]
(B) Fetal Growth
- Unlike olanzapine and quetiapine, aripiprazole is classified among the non-high-metabolic-risk SGAs. The Swedish national register study found that “other second-generation antipsychotics” (including aripiprazole) were not associated with increased risk of LGA infants or GDM.[3]
- However, the French prospective cohort found an increased rate of fetal growth retardation (OR 2.97; 95% CI 1.23–7.16) — the opposite direction from the macrosomia concern with olanzapine/quetiapine. This finding has not been replicated in larger studies and may reflect confounding, but it warrants awareness.[13]
Clinical Pearl — The Growth Paradox: While olanzapine and quetiapine are associated with LGA infants due to maternal metabolic effects, aripiprazole may carry a small risk in the opposite direction — fetal growth retardation — based on one French cohort.[13] This has not been confirmed in larger studies and may reflect confounding by maternal illness severity (women on aripiprazole may have more severe illness, poorer nutrition, or higher smoking rates). Standard growth monitoring with the 20-week anatomy scan is sufficient; serial growth ultrasounds are not routinely indicated for aripiprazole unless other risk factors are present.
Neurodevelopmental Outcomes — The Aripiprazole Signal
Aripiprazole is the only individual antipsychotic with a persistent (though unconfirmed) neurodevelopmental signal in the largest US birth cohort study.
- Straub et al. (2022; JAMA Internal Medicine): In a cohort of 3.4 million children with up to 14 years of follow-up, adjusted results for antipsychotics as a class did not suggest a substantially increased NDD risk (pooled aHR 1.08; 95% CI 1.01–1.17). However, aripiprazole was the exception: children whose mothers were dispensed aripiprazole during the second half of pregnancy had increased risks for any NDD (paHR 1.36; 95% CI 1.14–1.63), speech/language disorder (paHR 1.61; 95% CI 1.28–2.02), and behavioral disorder (paHR 1.63; 95% CI 1.18–2.26). The authors stated that “post hoc analyses to explore the positive association observed for aripiprazole did not allow us to rule out causality.”[4]
- Interpretation: The authors and subsequent commentators emphasized that this signal was inconsistent across analyses and that confounding due to maternal mental illness was not ruled out. Aripiprazole is increasingly used for MDD augmentation — a population that may differ systematically from women on other antipsychotics (e.g., more comorbid anxiety, different socioeconomic factors). The 2026 systematic review concluded that after adjusting for confounders, “the risk of neurodevelopmental disorders in school-age children does not seem to be increased” for antipsychotics as a class, though it acknowledged the aripiprazole-specific signal requires further study.[15][16]
Clinical Pearl — The Aripiprazole NDD Signal: How to Counsel: This is the most nuanced counseling point for aripiprazole. The signal is real (statistically significant in the largest study) but unconfirmed and potentially explained by confounding. Key points for patient discussions: (1) For antipsychotics as a class, the apparent NDD risk disappears after adjusting for maternal characteristics — the illness, not the medication, appears to drive the association. (2) Aripiprazole is the only exception, with a persistent signal that could not be fully explained by measured confounders. (3) However, the signal was inconsistent across sensitivity analyses, and unmeasured confounding (particularly by indication — aripiprazole is uniquely used for MDD augmentation) remains a plausible explanation. (4) No other study has replicated this specific finding.[4][15] This signal should be disclosed transparently but should not be the sole reason to avoid aripiprazole if it is the best agent for the patient’s psychiatric condition.
Maternal Management: The Metabolic “Green Zone” with Caveats
Aripiprazole has the most favorable metabolic profile among commonly used SGAs in pregnancy.
– GDM Risk: The Medicaid cohort study (1,924 aripiprazole-exposed pregnancies) found a crude GDM rate of 4.8% in continuers vs. 4.5% in discontinuers, with an adjusted RR of 0.82 (95% CI 0.50–1.33) — the only SGA with a point estimate below 1.0, suggesting no increased GDM risk.[2]
– Swedish Register Confirmation: Aripiprazole (classified under “other SGAs”) was not associated with increased GDM risk or LGA infants, in contrast to the high-metabolic-risk group (olanzapine, clozapine, quetiapine).[3]
– Akathisia: Aripiprazole’s most clinically significant side effect in pregnancy is akathisia (inner restlessness, inability to sit still). This can be mistaken for anxiety, agitation, or even a manic prodrome. In pregnancy, akathisia can be particularly distressing and may contribute to medication non-adherence. The FDA label lists akathisia as a common adverse reaction (incidence varies by indication: 8% in schizophrenia, 13% in bipolar mania, 25% in MDD adjunct).[1]
|
Risk Factor |
Aripiprazole Risk Level |
Comparison to Other SGAs |
Clinical Action |
|
|
Gestational Diabetes |
Lowest (aRR 0.82) |
Lower than quetiapine (1.28), risperidone (1.09), olanzapine (1.61) |
Standard GDM screening at 24–28 weeks; no early screen needed unless other risk factors |
|
|
Weight Gain |
Low |
Lower than olanzapine, quetiapine; comparable to ziprasidone |
Standard prenatal weight monitoring |
|
|
LGA Infant |
Not elevated |
Not in “high metabolic risk” group (unlike OLZ/CLZ/QTP) |
Standard growth monitoring |
|
|
Sedation |
Low |
Much lower than quetiapine or olanzapine |
Can be dosed in the morning; less fall risk |
|
|
Akathisia |
High (8–25% by indication) |
Higher than all other SGAs |
Monitor for restlessness; distinguish from anxiety; may require dose reduction or propranolol |
|
|
Prolactin Suppression |
Unique risk |
Only SGA that lowers prolactin |
Counsel about potential lactation failure; see Section 5 |
|
Clinical Pearl — Akathisia Masquerading as Anxiety: In pregnancy, aripiprazole-induced akathisia can be particularly challenging to diagnose because (1) anxiety is common in pregnancy, (2) the restlessness of akathisia can mimic or exacerbate anxiety disorders, and (3) patients may not recognize the motor component. If a pregnant patient on aripiprazole reports worsening “anxiety” or “inability to relax,” consider akathisia before adding an anxiolytic. A brief trial of dose reduction or addition of low-dose propranolol (which is generally safe in pregnancy) can be both diagnostic and therapeutic.
The Prolactin-Lactation Issue — A Critical and Unique Concern
This is aripiprazole’s most distinctive clinical consideration in the perinatal period and warrants prominent discussion.
The Pharmacology:
- Aripiprazole is a D₂ partial agonist. At the pituitary, where tonic dopamine inhibition suppresses prolactin release, aripiprazole acts as a functional antagonist of prolactin secretion — it lowers prolactin levels, often to below the normal range. This is the opposite effect of all other antipsychotics, which raise prolactin.[17]
The FDA Warning:
- The FDA label states: “Aripiprazole exposure during pregnancy and/or the postpartum period can lead to variable effects on milk supply in the post-partum period, including clinically relevant decreases in milk supply which may be reversible with discontinuation of the drug. There are also reports of aripiprazole exposure during pregnancy and no maternal milk supply in the post-partum period. Effects on milk supply are likely mediated through decreases in prolactin levels.”[6][18]
The Clinical Data:
A 2025 study from perinatal psychiatry services in India (Nanjundaswamy et al.) examined 35 women who continued aripiprazole through pregnancy and postpartum. The findings were striking:[5]
- 74% (26/35) experienced complete lactation failure (total absence of milk flow or minimal amounts for ≥7 days)
- 11% (4/35) had insufficient milk production
- Mean aripiprazole dose was 16.4 mg/day
- Mean duration of use was 20 months
Clinical Pearl — The Lactation Decision Point: The lactation data for aripiprazole are the most concerning of any SGA. A 74% complete lactation failure rate is clinically significant and must be discussed with patients who plan to breastfeed.[5] The FDA label confirms this is a class-specific effect mediated through prolactin suppression.[6] There are three management options: (1) If breastfeeding is a high priority, consider switching to a prolactin-neutral or prolactin-elevating antipsychotic (e.g., quetiapine) before delivery — but only if the patient can safely tolerate the switch. (2) If aripiprazole is the only effective agent, counsel the patient that breastfeeding may not be possible and have a formula feeding plan ready. (3) Some clinicians consider reducing the aripiprazole dose in the final 2 weeks of pregnancy to allow prolactin recovery, but this strategy is not evidence-based and carries relapse risk. The decision must be individualized, weighing maternal psychiatric stability against breastfeeding goals.
Pharmacokinetic Considerations in Pregnancy
Aripiprazole undergoes substantial pharmacokinetic changes during pregnancy that are clinically important.
- Metabolism: Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. Its active metabolite, dehydro-aripiprazole, represents ~40% of aripiprazole AUC at steady state. During pregnancy, CYP3A4 activity increases substantially (up to 2.3-fold by the third trimester), while CYP2D6 activity remains relatively stable or modestly increases.[1][19]
- Serum Level Decline: The Norwegian therapeutic drug monitoring study found that aripiprazole serum concentrations declined by 52% in the third trimester (95% CI -62% to -39%; p 0.001) — a statistically significant and clinically meaningful decline, second only to quetiapine (-76%) among SGAs studied.[7]
- PBPK Modeling: A PBPK model predicted that the AUC of the active moiety (aripiprazole + dehydro-aripiprazole) decreased by 12.6%, 38.8%, and 60.9% in the first, second, and third trimesters, respectively. Third-trimester concentrations were “entirely unable to reach its effective concentration (150 ng/mL).” The authors recommended that women in late pregnancy take at least 2 times their baseline dose.[20]
- 2026 Systematic Review: A systematic review of trimester-induced PK changes reported an aripiprazole plasma level decline of up to 76.8% in the third trimester — even more dramatic than the Norwegian TDM study estimate.[8]
- Placental Transfer: The mean placental transfer ratio of aripiprazole is approximately 56%, comparable to other SGAs and intermediate between quetiapine (~24%) and olanzapine (~72%).[21][22]
Clinical Pearl — The “Vanishing Dose” Problem: Aripiprazole’s 52–77% decline in serum levels during pregnancy is second only to quetiapine’s among SGAs.[7][8] Unlike olanzapine (which remains stable at -9%), aripiprazole requires active dose management during pregnancy. If a previously stable patient on aripiprazole begins to decompensate in the second or third trimester, declining drug levels should be the first consideration — not non-adherence or disease progression. Therapeutic drug monitoring (where available) is strongly recommended. PBPK modeling suggests doses may need to double by the third trimester to maintain therapeutic levels.[20] Importantly, the relatively moderate placental transfer ratio (56%) means that even with dose increases, fetal exposure increases proportionally but remains moderate.[21]
5. High-Yield “Clinic Ready” Tools: The Patient Script
Topic: Using Aripiprazole During Pregnancy
“Aripiprazole is one of our best options for keeping your weight and blood sugar healthy during pregnancy. Unlike some other medicines in this class, it does not increase your risk of developing diabetes during pregnancy, which is a real advantage.
The largest studies have not found it to cause birth defects. However, there are a few things we need to plan for. First, your body processes this medicine faster during pregnancy, so we may need to increase your dose as the pregnancy progresses to keep it working well. We’ll monitor how you’re feeling closely.
Second, this medicine can sometimes make it harder to produce breast milk after delivery. If breastfeeding is important to you, we should talk about that now so we can make a plan together.
Lastly, like all medicines in this class, there is a small chance the baby could be a little jittery or restless for a few days after birth, but this is temporary and something the pediatricians know how to manage.”
6. High-Yield “Clinic Ready” Tools: EMR Documentation Template
Pregnancy Consultation: Aripiprazole Management
– Current Dose: [X] mg/day.
– Indication: [Bipolar I Disorder / Schizophrenia / MDD Augmentation / Other].
– Teratogenicity Counseling: Informed patient that published epidemiologic studies have not established aripiprazole as a cause of major birth defects. The MGH National Pregnancy Registry (158 exposed women) found an adjusted OR of 1.35 (95% CI 0.43–4.20) — not significant. The 2016 Medicaid cohort (1.36 million pregnancies) found no increased risk for aripiprazole specifically. Background risk of major birth defects is 2–4%.
– Neurodevelopmental Counseling: Discussed the unconfirmed signal from the Straub et al. 2022 US birth cohort study showing a possible association between aripiprazole exposure and neurodevelopmental disorders (paHR 1.36; 95% CI 1.14–1.63). Explained that this signal was inconsistent across analyses, could not rule out confounding by indication, and has not been replicated. For antipsychotics as a class, the NDD risk disappears after confounding adjustment.
– Metabolic Monitoring: Discussed low risk for GDM (aRR 0.82 in Medicaid cohort — lowest among SGAs). Standard GDM screening at 24–28 weeks. Standard prenatal weight monitoring.
– Akathisia Monitoring: Discussed risk of akathisia (inner restlessness) which may worsen or emerge during pregnancy. Patient instructed to report restlessness, inability to sit still, or worsening “anxiety” that feels physical rather than cognitive.
– Lactation Counseling: ⚠️ Discussed FDA warning that aripiprazole may decrease or eliminate milk supply postpartum due to prolactin suppression. Recent clinical data show 74% complete lactation failure in women continuing aripiprazole through pregnancy/postpartum. Patient’s breastfeeding plan: [Plans to breastfeed / Does not plan to breastfeed / Undecided]. If breastfeeding desired: [Plan to switch agent before delivery / Accept risk and have formula backup / Dose reduction strategy discussed].
– Pharmacokinetic Counseling: Discussed that aripiprazole levels decline by 52–77% during pregnancy due to CYP3A4 induction. Dose adjustment likely needed in second/third trimester. Therapeutic drug monitoring will be considered.
– Monitoring Plan:
- Standard 20-week anatomy scan.
- Therapeutic drug monitoring of aripiprazole levels [baseline obtained / to be obtained].
- Pediatrician/neonatologist notified of maternal aripiprazole use prior to delivery.
- Neonatal observation for EPS/withdrawal symptoms after delivery.
- If breastfeeding attempted: monitor infant for dehydration and inadequate weight gain.
– Clinical Rationale: Aripiprazole’s favorable metabolic profile (lowest GDM risk among SGAs) and established teratogenic safety make it a reasonable choice for pregnancy, particularly in patients with pre-existing metabolic risk factors. The unconfirmed NDD signal and lactation concerns have been discussed and weighed against the risks of medication change or discontinuation. Continuation recommended with dose optimization and lactation planning.
Pregnancy Exposure Registry
The National Pregnancy Registry for Atypical Antipsychotics (based at Massachusetts General Hospital) monitors pregnancy outcomes in women exposed to atypical antipsychotics including aripiprazole. Healthcare providers are encouraged to register patients: 1-866-961-2388 or womensmentalhealth.org.[1]
References
- ABILIFY. Food and Drug Administration. Updated date: 2025-01-29.
- Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. Park Y, Hernandez-Diaz S, Bateman BT, et al. The American Journal of Psychiatry. 2018;175(6):564-574. doi:10.1176/appi.ajp.2018.17040393.
- Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. Heinonen E, Forsberg L, Nörby U, Wide K, Källén K. CNS Drugs. 2022;36(5):529-539. doi:10.1007/s40263-022-00908-2.
- Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. Straub L, Hernández-Díaz S, Bateman BT, et al. JAMA Internal Medicine. 2022;182(5):522-533. doi:10.1001/jamainternmed.2022.0375.
- Lactation-Related Side Effects of Aripiprazole: A Study From Perinatal Psychiatry Services in India. Nanjundaswamy MH, Shah A, Lotlikar S, et al. Journal of Clinical Psychopharmacology. 2025 May-Jun 01;45(3):258-266. doi:10.1097/JCP.0000000000001997.
- Aripiprazole. Food and Drug Administration. Updated date: 2024-11-13.
- Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition. Westin AA, Brekke M, Molden E, et al. Clinical Pharmacology and Therapeutics. 2018;103(3):477-484. doi:10.1002/cpt.770.
- Trimesters Induced Changes in Pharmacokinetic Parameters of Antipsychotics. Adhayanti I, Robiyanto R, Bahar MA, Wahyudin E. Archives of Women’s Mental Health. 2026;29(1):16. doi:10.1007/s00737-025-01665-z.
- Reproductive Safety of Aripiprazole: Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Freeman MP, Viguera AC, Góez-Mogollón L, et al. Archives of Women’s Mental Health. 2021;24(4):659-667. doi:10.1007/s00737-021-01115-6.
- Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. Huybrechts KF, Hernández-Díaz S, Patorno E, et al. JAMA Psychiatry. 2016;73(9):938-46. doi:10.1001/jamapsychiatry.2016.1520.
- Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. Huybrechts KF, Straub L, Karlsson P, et al. JAMA Psychiatry. 2023;80(2):156-166. doi:10.1001/jamapsychiatry.2022.4109.
- Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-Analysis of Congenital Malformations and Prenatal Outcomes. Wang E, Liu Y, Wang Y, et al. CNS Drugs. 2025;39(1):1-22. doi:10.1007/s40263-024-01131-x.
- Exposure to Aripiprazole During Embryogenesis: A Prospective Multicenter Cohort Study. Bellet F, Beyens MN, Bernard N, et al. Pharmacoepidemiology and Drug Safety. 2015;24(4):368-80. doi:10.1002/pds.3749.
- Aripiprazole and Pregnancy: A Retrospective, Multicentre Study. Galbally M, Frayne J, Watson SJ, Snellen M. Journal of Affective Disorders. 2018;238:593-596. doi:10.1016/j.jad.2018.06.004.
- Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, and Other Neurodevelopmental Outcomes Associated With Antipsychotic Drug Exposure During Pregnancy. Andrade C. The Journal of Clinical Psychiatry. 2022;83(3):22f14529. doi:10.4088/JCP.22f14529.
- Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children. Kaplan CA, Poels EMP, van den Heuvel MI, et al. Journal of the American Academy of Child and Adolescent Psychiatry. 2026;65(3):354-368. doi:10.1016/j.jaac.2025.04.008.
- Management of First-Episode Psychosis and Schizophrenia (SCZ) (2023). Marlene Arias-Reynoso DNP PMHNP-BC, Jennifer L. Bell MD, Pamela Blueford LICSW, et al. Department of Veterans Affairs.
- ARIPIPRAZOLE. Food and Drug Administration. Updated date: 2025-12-22.
- Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Clinical Pharmacokinetics. 2021;60(12):1569-1582. doi:10.1007/s40262-021-01041-x.
- Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation. Zheng L, Tang S, Tang R, et al. Clinical Pharmacokinetics. 2021;60(5):623-635. doi:10.1007/s40262-020-00962-3.
- Perinatal Use of Aripiprazole: Plasma Levels, Placental Transfer, and Child Outcome in 3 New Cases. Windhager E, Kim SW, Saria A, et al. Journal of Clinical Psychopharmacology. 2014;34(5):637-41. doi:10.1097/JCP.0000000000000171.
- Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis. Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M. Therapeutic Drug Monitoring. 2020;42(2):245-254. doi:10.1097/FTD.0000000000000692.
Responses